QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Vir Biotechnology, Inc. (VIR)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
3

Buy limit 11.80 at EMA21 support (11.76) - a trend-aligned pullback with price above SMA50 11.18 and SMA200 9.75 and MACD 0.49 > 0; no earnings or dividend event through the 15-day horizon 2026-12-04. Structural swingLow 11.30 minus buffer 0.16 = 11.14, widened by the pullback ATR floor to 11.00 (1.0xATR); targets 13.40 (entry + 2.0xATR) and 14.60 (entry + 3.5xATR); R/R 2.00.

Analysis as of 2026-11-12· more than 2 trading days ago

Company overview

Vir Biotechnology, Inc. is an immunology company focused on developing therapeutic solutions for infectious diseases. Its pipeline includes candidates for SARS-CoV-2, hepatitis B, influenza A, and HIV. The company collaborates with various organizations and maintains strategic partnerships to advance its research and development efforts.

Fundamental

fair
Fundamental3
Mixed fundamentals

Vir Biotechnology has a strong balance sheet but lacks recurring revenue, making it a speculative, catalyst-driven company.

Mixed fundamentals: effectively no recurring revenue and heavy cash burn, offset by zero financial debt, roughly $900M of cash and investments, and a newly reported positive pivotal Phase 3 win in hepatitis delta. Balance-sheet strength and the clinical catalyst are real, but a binary single-asset outcome, rapid dilution and an absent earnings base keep this a speculative, catalyst-driven profile rather than a fundamentally anchored one.

Sentiment

fair
Sentiment3
Forming / two-sided

Sentiment is mixed, with recent trial success offset by earnings misses and no immediate catalysts.

Dominant catalyst is the announced 2026-11-09 pivotal Phase 3 ECLIPSE 1 win for elebsiran/tobevibart in chronic hepatitis delta (44% vs 0% virologic response, all endpoints met), which the tape rewarded with a ~22% single-session move and a follow-on price-target cluster at $17–$23, set against a 2026-11-04 Q3 revenue miss and per-share loss that in-window coverage scored negative. The 14-day media read is mixed at a polarity score of roughly +0.17 against a baseline of roughly +0.13 (delta flat); the severe red-flag screen is clean, but a moderate conflicting-catalysts flag fires because both the bullish Phase 3 leg and the bearish earnings leg sit inside the actionable window on a complete array — moderate red-flag cap applied, with the anchoring catalyst already two days old and partially priced and no scheduled driver inside 30 trading days.

Technical

fair
Technical3
Trend-aligned pullback

The stock is in a pullback within an intact uptrend, with support levels offering a favorable risk-reward setup.

Mixed-to-constructive: the medium-term trend is intact (price 12.12 above SMA20 11.47, SMA50 11.18, SMA200 9.75 and EMA21 11.76, ADX14 25.56 rising, MACD 0.49/0.34/0.15 still positive), but the short-term tape weakened after a 16% two-day pullback from 14.38 (close below EMA9 12.29 and VWAP 12.37, RSI cooled 68.3 to 54.0, MACD histogram contracted 0.23 to 0.15, -6.4% distribution day closing near the low). Because price sits above the SMA50 with MACD > 0 the dip is trend-aligned, not countertrend, so a pullback limit at EMA21 support with a structure-based stop yields an acceptable 2.00 R/R and a score of 3 supports the trade.

You’re looking at 2026-11-12 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.